Enterococci have emerged as significant nosocomial pathogens. Enterococci with resistance to commonly used antibiotics are appearing more frequently. We encountered at our institution several infections caused by Enterococcus faecium with high-level resistance to ampicillin, vancomycin, and gentamicin. The optimal antibiotic therapy for serious infections with unusually resistant enterococci has not been established. Using time-kill studies, we tested the effectiveness of various antibiotic combinations against 15 isolates of multidrug-resistant enterococci. No antibiotic was consistently effective when used alone. The combination of ampicillin plus ciprofloxacin was bactericidal for the 12 isolates for which the ciprofloxacin MIC was c8 ig/ml. The combination of ciprofloxacin plus novobiocin also demonstrated activity against these isolates. No combination was found to be bactericidal for the remaining three isolates, which were highly ciprofloxacin resistant. These antibiotic combinations may be important for the future treatment of serious infections caused by these resistant pathogens.
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Nosocomial infections with enterococci have been reported with increasing frequency in the past several years (24) . Antibiotics used against enterococci are typically bacteriostatic when used alone. Therefore, the mainstay of therapy for serious enterococcal infections includes a penicillin (or a glycopeptide antibiotic) in combination with an appropriate aminoglycoside. However, enterococci are becoming increasingly resistant to traditional antimicrobial agents. High-level aminoglycoside resistance has become commonplace (15, 20) . Penicillin resistance may or may not be P-lactamase mediated (1, 6, 18, 22) .
Vancomycin resistance was recently reported for enterococci (8, 13, 23, 28) . Two distinct patterns of vancomycin resistance have been documented for most enterococci. Class A strains have the vanA gene, are able to transfer resistance by conjugation, and are also resistant to teicoplanin (13, 26) . Class B strains generally do not transfer resistance and remain susceptible to teicoplanin (23, 28) ; however, transfer of resistance was recently observed for Enterococcus faecalis and E. faecium (21) . Teicoplanin resistance has also been noted to develop in a clinical isolate of E. faecium (9) with vanB.
Over the course of 10 months, we identified six isolates of E. faecium with high-level resistance to ampicillin, vancomycin, and gentamicin. Five of these isolates originated from patients with bacteremia. There is no proven effective therapy for such multidrug-resistant enterococci. In this investigation, we determined the effect of various combinations of antibiotics on the killing of these and other E. faecium isolates resistant to ampicillin, gentamicin, and vancomycin.
MATERIALS AND METHODS
Patients. From August 1991 through May 1992, six clinical isolates of E. faecium resistant to ampicillin and vancomycin were collected at our hospital. The six isolates were widely separated in both time and location at our institution during * Corresponding author. the 10-month period. Five patients were located on the medical service (including one patient in the medical intensive care unit) and one patient was in the surgical intensive care unit at the time of the positive cultures. The length of hospitalization ranged from 9 to 41 days. Five patients were bacteremic, including two patients with urosepsis, and one patient had wound colonization. All patients had received beta-lactam antibiotics, primarily ampicillin and broad-spectrum cephalosporins, in the month prior to the occurrence of the positive cultures. Three patients had also received van Killing rates. Time-kill studies were performed with logphase cultures adjusted to approximately 106 CFU/ml in supplemented Mueller-Hinton broth. The following antibiotic concentrations were used for the time-kill experiments: van- comycin, 20 p,g/ml; ampicillin, 20, 40, 80, and 160 ,ug/ml; novobiocin, 50 ,ug/ml; ciprofloxacin, 1 and 3 p,g/ml; and teicoplanin, 20 ,ug/ml. These concentrations were chosen because they generally reflect intermediate to maximal clinically achievable concentrations in blood. The higher concentrations of ampicillin were also tested to demonstrate any dose-response relationship between ampicillin and killing rates. Clinically achievable levels of novobiocin in serum range from 20 to 100 jig/ml (12) . Each antibiotic was tested alone in the time-kill experiments. The following two-drug combinations were also analyzed: ampicillin plus ciprofloxacin, ampicillin plus novobiocin, ampicillin plus vancomycin, ampicillin plus teicoplanin, vancomycin plus ciprofloxacin, teicoplanin plus ciprofloxacin, and novobiocin plus ciprofloxacin. In addition, the following three-drug combinations were studied: ampicillin plus vancomycin plus ciprofloxacin, ampicillin plus novobiocin plus ciprofloxacin, and ampicillin plus teicoplanin plus ciprofloxacin. 
RESULTS
For all 15 isolates of E. faecium, the MIC of both ampicillin and vancomycin was >64 ,ug/ml (Table 1) ; none of these isolates were found to produce penicillinase. All isolates expressed high-level resistance to gentamicin (MIC, >2,000 ,ug/ml) as well as resistance to rifampin. Seven isolates were resistant to teicoplanin.
Time-kill studies revealed that no antibiotic was consistently effective when used alone ( Table 2) . Because of differences in killing rates, the 15 isolates were grouped on the basis of ciprofloxacin susceptibility for further analysis.
Ciprofloxacin MICs were 58 p,g/ml for group 1 isolates (n = 12), and >32 ,ug/ml for group 2 isolates (n = 3). All group 2 isolates were resistant to teicoplanin as well. For the group 1 isolates, only combinations involving higher concentrations of ampicillin and ciprofloxacin showed bactericidal activity. The combination of ampicillin (40 ,ug/ml) plus ciprofloxacin (3 ug/ml) displayed the highest bactericidal activity, with changes in log1o CFU of -1.90 + 0.83 and -3.96 + 0.50 at 4 and 24 h, respectively. Repeat time-kill experiments with the same 12 isolates resulted in changes in log1o CFU of -2.01 + 0.95 and -4.10 ± 0.73, respectively, for the same combination. The decrease in CFU was much higher than that seen with either antibiotic alone at 24 h. Lower concentrations of ampicillin and ciprofloxacin were not effective ( 20 ,ug/ml resulted in changes in log1o CFU of -1.11 and -3.25 at 4 and 24 h, respectively. Ampicillin at 40 ,ug/ml caused changes in log1o CFU of -1.41 and -4.25, respectively. Ciprofloxacin at 1 ,ug/ml led to changes in log1o CFU of -3.25 and -1.19, respectively. Ciprofloxacin at 3 p,g/ml resulted in changes in log1o CFU of -2.97 and -4.56, respectively. The combinations of ampicillin plus ciprofloxacin were indifferent. Novobiocin alone caused changes in log1o CFU of -0.14 and -1.38 at 4 and 24 h, respectively.
The addition of novobiocin to ciprofloxacin did not enhance the killing of this strain.
DISCUSSION
Enterococci are now the second most common nosocomial pathogens in the United States (24) . Increasing resistance patterns have made therapy problematic. Cases of infections with unusually resistant enterococci have occurred (8, 14, 19) ; these include the 10 cases of bacteremia in this report. To date, recommendations for the treatment of ampicillin-, vancomycin-, and aminoglycoside-resistant enterococci have not been established (10) . Our study suggests that the combination of ampicillin plus ciprofloxacin may be an effective combination against many of these multidrugresistant enterococci.
The overall activity of quinolone antibiotics against enterococci is disappointing. When used alone, ciprofloxacin displays poor killing of enterococci (4, 17) . Similarly, the combination of ciprofloxacin plus beta-lactam antibiotics has generally been ineffective against enterococci. For example, Moody et al. (16) found indifference for the combination of ciprofloxacin plus azlocillin against 10 strains of E. faecalis and E. avium. Similarly, Hodin and Painter (11) found indifference for the combination of ampicillin plus ciprofloxacin against 25 strains of E. faecalis. Wise and Andrews (29) found indifference or "partial synergy" for 10 strains of E. faecalis with the combination of penicillin plus ciprofloxacin. All of these investigators used the checkerboard technique for determining antibiotic activity. Femandez-Guerrero et al. (4) performed time-kill studies with lower concentrations of ciprofloxacin plus penicillin against two susceptible strains of E. faecalis and found the activity of the combination to be similar to that of penicillin alone. This observation was also reflected during in vivo experiments done by the same authors (4). In contrast, Grimm (7) demonstrated synergy of ampicillin plus ciprofloxacin against 10 strains of gentamicin-resistant enterococci not identified to the species level. The susceptibility of these strains to ampicillin was not stated. Livornese et al. (14) found synergy of ciprofloxacin plus rifampin plus gentamicin for one strain of E. faecium. This strain differed from ours by the lack of high-level gentamicin and rifampin resistance. In our study, the combination of ampicillin plus ciprofloxacin was bactericidal against all E. faecium strains without highlevel ciprofloxacin resistance (MIC, <8 ,ug/ml). While only three strains with high-level ciprofloxacin resistance (MIC, 232 ,ug/ml) were studied, there was a trend toward slightly increased killing when ciprofloxacin was added to each ampicillin concentration. This result may indicate some interaction between ampicillin and ciprofloxacin even for these strains. For E. faecalis ATCC 29212 and for two other ampicillin-susceptible strains ofE. faecalis (data not shown), we found that the combination of ampicillin plus ciprofloxacin was indifferent. Whether synergy of ampicillin plus ciprofloxacin is a property restricted only to E. faecium remains to be determined.
For our group 1 isolates, the addition of vancomycin or teicoplanin to the combination of ampicillin plus ciprofloxacin diminished killing at 4 h. This result was somewhat surprising, since the addition of vancomycin to ampicillin or penicillin generally has resulted in indifference and occasionally synergy in other studies (2, 5, 8) . A possible explanation for this finding is that the addition of vancomycin may have slowed bacterial replication and removed the bacteria from the log phase of growth, thereby interfering with the activity of ampicillin plus ciprofloxacin. The precise molecular basis for the effect that we observed remains unknown.
Novobiocin is a DNA gyrase inhibitor that has been available for the treatment of gram-positive pathogens for 30 years (12) . Because of toxicity and the development of beta-lactam antibiotics, novobiocin is rarely used at present.
We demonstrated appreciable killing (-2.54 log1o CFU) of our group 1 isolates with the combination of ciprofloxacin plus novobiocin. Venuti et al. (27) reported similar findings when using a 10-fold-lower concentration of novobiocin, including synergy for some isolates when novobiocin was combined with a quinolone. While further studies will be needed to determine whether this finding is a consistent one, this combination may be potentially useful in patients allergic to penicillin.
Antibiotic activity in vitro does not always correlate with in vivo effectiveness. The effects of protein binding, distribution, tissue penetration, and the constantly changing antibiotic concentrations that occur in vivo are not accounted for during in vitro studies. In particular, the efficacy of novobiocin may be limited by its high degree of protein binding (12) . Furthermore, the growing prevalence of ciprofloxacin resistance (25) and the possibility of the development of resistance during therapy may limit the usefulness of this drug. Nevertheless, there is no proven effective therapy for multidrug-resistant enterococci. This problem underscores the need to investigate new combinations and develop new agents for these multidrug-resistant strains.
In summary, we found that combinations of ciprofloxacin plus ampicillin or novobiocin have significant in vitro activity against many multidrug-resistant enterococci. The activity of these combinations is decreased by high-level ciprofloxacin resistance. For strains with high-level ciprofloxacin resistance, very high doses of ampicillin-with or without ciprofloxacin-may prove useful. Further in vivo studies examining the effectiveness of these antibiotic combinations will be necessary before firm treatment recommendations can be established.
